Vamsipedia · Clinical AI

Biologic Select

After the first dose

Response, remission, relapse

Four to six months grades the response and decides a switch. Twelve months is the earliest you may talk about on-treatment clinical remission. Relapse after a missed dose is not the same as non-response. Working agent: Benralizumab.

Follow-up values

Leave blank until the review visit. Baseline lives on the Selector.

Response (4–6 months)

Set the 4-to-6-month review now

The guideline anchors every switching decision to a defined assessment window. Agree the treatment goals with the patient before the first injection, and enter the follow-up values here when you have them.

  • Exacerbations≥50% reduction in annualised rate3/yearpending
  • Systemic steroid≥50% dose reduction, or bursts eliminatedNonepending
  • Symptom controlACT ≥20 or rise of ≥3; ACQ ≤1.5 or fall of ≥0.5ACT 14pending
  • Lung functionStable or ≥5% predicted gain (or ≥100 mL)FEV₁ 62%pending

On-treatment remission (12 months)

Enter follow-up at 12 months to test this patient against on-treatment clinical remission. Until then the criteria below are the target you should write into the notes at initiation.

  • Twelve-month windowpending

    Remission is a 12-month construct. Response at 4–6 months is necessary but not sufficient.

  • No exacerbationspending

    Zero severe exacerbations (OCS burst, ED, or admission) over the 12 months.

  • No systemic corticosteroidmet

    No maintenance OCS and no rescue bursts in the window.

  • Symptom controlpending

    ACT ≥20 or ACQ-5 <1.5, sustained — not a single good clinic visit.

  • Stable, optimised lung functionpending

    FEV₁ within ~10% of the post-biologic baseline, not a return to the pre-treatment trough.

  • Patient and clinician agree it is controlledpending

    Shared decision, documented. Remission is not a lab diagnosis.

  • Reliever use not excessive (optional)pending

    SABA or MART reliever on ≤2 days/week. Supportive, not required by every consensus statement.

Remission on treatment is not a reason to stop

Off-treatment remission is a research construct. COMET showed that withdrawing a successful anti-IL-5 is followed by eosinophil rebound and return of exacerbations. Keep the biologic; write the remission in the notes.

Relapse

Three different events get called “the drug stopped working”. Only one of them is a reason to switch class.

On-treatment loss of response

New exacerbations or a falling ACT after an initial response, while doses are being given on time. This is not the same as a missed-dose rebound.

  • Was the trial long enough the first time, and is adherence to ICS-LABA intact? A biologic will not rescue an unused inhaler.
  • Re-examine the diagnosis: vocal cord dysfunction, bronchiectasis, EGPA, cardiac disease and obesity hypoventilation declare themselves at this moment.
  • Untreated CRSwNP, GERD, OSA and anxiety mimic biologic failure.
  • Is the target still right? Exacerbations stopped but ACT unchanged is a response — residual symptoms may not be type 2 inflammation.
  • Neutralising anti-drug antibodies are uncommon with these agents; do not order them as a first step.
  • If Benralizumab has truly lost effect after a fair trial, switch by the ACCP sequence rather than stacking a second biologic.

Relapse after withdrawal or a missed dose

COMET (mepolizumab) is the clearest map: stopping a successful anti-IL-5 is followed by eosinophil return and a rise in exacerbations over the next year. That is the disease coming back, not a new endotype.

  • Do not stop a biologic to 'see if they still need it' until at least 12 months of on-treatment clinical remission, and even then only in a supervised pathway.
  • Restart the same agent if relapse follows a planned withdrawal of a super-responder — the target has not changed.
  • Benralizumab: eosinophils are depleted by ADCC. After a missed 8-weekly dose they can rebound; this is not anti-IL-5 failure. Resume, and reload if more than two intervals have been missed (product labelling).
  • Depemokimab: a missed dose is a 6-month gap. Diarise both annual injections at initiation.
  • Dupilumab stop: FeNO and eosinophils rebound, dermatitis and polyps can flare. Restart the same dose band unless EGPA has been unmasked.
  • Omalizumab: restart using the original baseline IgE × weight table — do not re-measure IgE on or immediately after treatment.
  • No washout is required between biologics; start the new agent when the next dose of the old one would have been due.

Biomarker rebound is not the same as clinical relapse

Eosinophils will rise when an anti-IL-5 is held. FeNO will rise when dupilumab is held. Treat the patient, not the number — unless the rebound is accompanied by exacerbations, steroid restart, or a falling ACT.

  • A rising eosinophil count off anti-IL-5 without symptoms can be watched for a short interval; restart if control slips.
  • Never use a suppressed-on-treatment eosinophil count to choose the next biologic. Stratify on the pre-treatment (or 12-month peak) values.
  • If two or more downstream agents have failed and the phenotype is indeterminate, the upstream alarmin (TSLP) is the rational option, availability permitting.